Denosumab biosimilar - Intas Pharmaceuticals

Drug Profile

Denosumab biosimilar - Intas Pharmaceuticals

Latest Information Update: 31 Aug 2016

Price : $50

At a glance

  • Originator Intas Pharmaceuticals
  • Class Antineoplastics; Monoclonal antibodies; Osteoporosis therapies
  • Mechanism of Action RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Postmenopausal osteoporosis

Most Recent Events

  • 31 Aug 2016 Preclinical trials in Postmenopausal osteoporosis in India (SC) before August 2016
  • 31 Aug 2016 Intas Pharmaceuticals plans a phase III trial for Postmenopausal osteoporosis in India (CTRI/2015/07/006065)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top